viewBiocept Inc

Full interview: Biocept receives CE-IVD Mark for Target Selector test kit allowing sales in E.U.

Biocept (NASDAQ: BIOC) President and CEO Michael Nall joined Proactive’s Steve Darling with news the company can start selling their Target Selector molecular assay EGFR Kit after receiving their CE-IVD Mark that allows Biocept to commercialize its kits throughout the European Union and other CE Mark geographies.

Nall discusses what this means for the company and also shared details about their COVID-19 response especially when it comes to testing.

Quick facts: Biocept Inc

Price: 0.4153 USD

Market: NASDAQ
Market Cap: $54.45 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...



Full interview: Phunware beats out major company to become app of choice for...

Phunware (NASDAQ: PHUN) CEO Alan Knitowski joined Steve Darling from Proactive Vancouver with news the company has beat out giant Salesforce to become of the app of choice for the re-election campaign of Donald J Trump and Mike Pence. Knitowski talks about winning that contract and what their...

1 hour, 5 minutes ago

2 min read